On this page
When arteries in the legs narrow badly enough, the tissue starts to die and amputation becomes the alternative. That gives this condition something most in this field lack: an endpoint nobody can argue about. Stem cell therapy for peripheral vascular disease has been studied in randomised placebo-controlled trials against exactly that endpoint.
The controlled evidence
A double-blind randomised placebo-controlled study assessed allogeneic marrow-derived cells in critical limb ischaemia — A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.
Other work examined combination cell products for therapeutic angiogenesis in severe limb ischaemia — Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product.
Autologous cells have been studied in the specific problem of chronic ulcers in diabetic feet caused by limb ischaemia — Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients.
Placebo-controlled and double-blind, in a condition with hard endpoints. That is a genuinely better evidence base than most pages on this site describe.
Claudication is a different target
Intermittent claudication is calf pain on walking that settles with rest. It is limiting and it is not limb-threatening, and most patients never progress to critical ischaemia.
A research network designed a structured study of cell injection in this group — Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells — with detailed baseline assessment of arterial anatomy and muscle perfusion published separately — Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease.
That level of baseline measurement is what distinguishes research from treatment. The investigators wanted to know what they were treating before claiming to have changed it.
For claudication specifically, supervised exercise therapy has strong randomised evidence and frequently matches procedural treatment for walking distance. It is also close to free.
Why the endpoint matters so much here
Amputation-free survival cannot be talked up. Either the limb is there at twelve months or it is not.
Wound healing is similarly checkable. An ulcer is closed or it is not, and a photograph settles it.
Compare that with pain scores and quality-of-life questionnaires, which respond strongly to expectation and attention, and it becomes clear why this literature carries more weight than its size alone suggests.
Diabetic foot ulcer covers the closely related wound evidence, which is among the better-evidenced applications in this field.
What is being attempted biologically
The aim is angiogenesis — promoting the growth of new small blood vessels to improve perfusion where the main arteries are blocked and cannot be reopened.
That is a plausible target with a measurable outcome, and it does not require cells to become tissue. It requires them to signal, which fits current thinking about how these cells act.
It is also the reason these patients are studied: they are typically people in whom bypass surgery and angioplasty have failed or are not possible. There is no established alternative left.
Being out of options is the right context for an experimental treatment. It is not the context most clinic patients are in.
What must happen regardless
Smoking cessation, which affects outcomes in this condition more than any treatment discussed here.
Antiplatelet therapy and statins, with large randomised evidence for reducing heart attack and stroke in this group — peripheral arterial disease is a marker of arterial disease everywhere.
Assessment by a vascular surgeon for revascularisation, because an artery that can be reopened should be.
Diabetes control and structured foot care where diabetes is present. Type 2 diabetes covers the underlying condition.
How it is delivered
Intramuscular injection into the calf and thigh muscles of the affected leg, usually at multiple sites in one session, is the commonest approach in trials.
Intra-arterial delivery into the leg circulation has also been studied.
Cells may be autologous from marrow, or allogeneic from donated tissue. Autologous therapy covers what a harvest involves.
Both routes are procedures with their own risks, particularly in patients who are often frail and on antiplatelet drugs.
How the disease is assessed
The ankle-brachial index compares blood pressure at the ankle with that in the arm, and is the standard first measurement. It becomes unreliable in diabetes, where calcified vessels resist compression and produce falsely reassuring numbers.
Toe pressures and transcutaneous oxygen measurement are used where that happens, and imaging — duplex ultrasound, CT or MR angiography — maps where the blockages are and whether they can be treated.
Any proposal for treatment should follow that mapping rather than precede it. Knowing which vessels are blocked determines whether a bypass or angioplasty is possible, and that possibility outranks everything experimental.
If a clinic proposes injections without having seen imaging of the arteries, it is treating a symptom without knowing the anatomy causing it.
Risks
Injection site pain and bruising, more pronounced in patients on antiplatelet or anticoagulant treatment.
Infection risk in a limb with compromised blood supply, where healing is poor by definition and any breach of skin is a concern.
Marrow harvest complications where autologous cells are used, in a patient group with substantial cardiovascular risk.
Documented adverse events covers what has been reported across the field.
Questions worth asking
- Is this critical limb ischaemia or claudication? The evidence differs.
- Has a vascular surgeon confirmed that revascularisation is not possible?
- Have I stopped smoking, and am I on a statin and antiplatelet?
- What outcome will be measured — the wound, the walking distance, or how I feel?
- Is there a trial I could join?
What the evidence levels mean explains the grading used here.
Frequently asked questions
Is there placebo-controlled evidence?
Yes — a double-blind randomised placebo-controlled phase I/II study in critical limb ischaemia, which is better than most of this field offers.
Does it work for leg pain on walking?
Claudication is a different target. Supervised exercise therapy has strong randomised evidence there and often matches procedural treatment.
Can it save my leg?
Amputation-free survival has been studied as an endpoint. That is the right question to ask, and the honest answer is that the evidence is early.
Should I try this before bypass surgery?
No. Trials recruited patients in whom revascularisation had failed or was not possible. An artery that can be reopened should be.
Does smoking matter?
More than anything else discussed on this page. Continuing to smoke undermines every treatment for this condition.
How are the cells given?
Usually by multiple intramuscular injections into the affected leg, sometimes intra-arterially. Not as a general intravenous infusion.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.